drug
BYLVAY
updated 5mo agoby Ipsen SA
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying BYLVAY
- phase3Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC
- phase3Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
- phase3An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
- phase3Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
- phase3This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2
- —Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis
- phase3Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
News(2)
- Regeneron wins FDA approval to challenge Ipsen for rare bone disease marketRegeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.biospace · 1mo ago
- Ipsen’s Bylvay fails key trial in children with rare liver diseaseIpsen disclosed that Bylvay failed a Phase 3 study for biliary atresia, a serious liver disease that leads the bile ducts to become blocked in babies. Babies with the disease can get a Kasai proced…endpoints · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that